Sigma-Aldrich and CPC Scientific Signs Distribution Agreement for Custom Peptide Libraries
News Jan 30, 2009
Sigma-Aldrich has announced that it has signed a distribution agreement with CPC Scientific. Under the terms of the agreement, CPC Scientific will offer Sigma-Aldrich's PEPscreen® custom peptide libraries to life science researchers and pharmaceutical companies in North America.
Sigma- Aldrich has developed a proprietary synthesis platform that enables the high throughput production of milligram quantities of peptides, which are ideal for producing custom peptide libraries applicable to peptide based drug discovery.
"In Sigma-Aldrich, we've found an experienced partner for the production of custom peptide libraries," said Dr. Shawn Lee, President & CEO of CPC Scientific. "The addition of PEPscreen custom peptide libraries to our portfolio benefits our customers by addressing the early research phase of peptide screening in the drug discovery workflow."
Sigma-Aldrich's peptide synthesis process significantly reduces the time required for peptide library development, reducing costs in the drug development process. The company's customized peptide libraries are utilized by the biotechnology industry to target active areas of small biological molecules with potential therapeutic properties.
"Our PEPscreen technology enables small scale, early stage drug candidate screenings," said Stacey Hoge, Senior Product Manager at Sigma-Aldrich. "CPC's close association with the pharmaceutical and biotechnology industry provides great opportunities for Sigma-Aldrich to further engage drug discovery researchers."
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE